Iron dysregulation in COVID-19 and reciprocal evolution of SARS-CoV-2: Natura nihil frustra facit.

MD simulations evolved variants ferritin-transferrin paradox host proteases hypoxia iron homeostasis

Journal

Journal of cellular biochemistry
ISSN: 1097-4644
Titre abrégé: J Cell Biochem
Pays: United States
ID NLM: 8205768

Informations de publication

Date de publication:
03 2022
Historique:
received: 13 10 2021
accepted: 16 12 2021
pubmed: 9 1 2022
medline: 5 4 2022
entrez: 8 1 2022
Statut: ppublish

Résumé

After more than a year of the COVID-19 pandemic, SARS-CoV-2 infection rates with newer variants continue to devastate much of the world. Global healthcare systems are overwhelmed with high positive patient numbers. Silent hypoxia accompanied by rapid deterioration and some cases with septic shock is responsible for COVID-19 mortality in many hospitalized patients. There is an urgent need to further understand the relationships and interplay with human host components during pathogenesis and immune evasion strategies. Currently, acquired immunity through vaccination or prior infection usually provides sufficient protection against the emerging variants of SARS-CoV-2 except Omicron variant requiring recent booster. New strains have shown higher viral loads and greater transmissibility with more severe disease presentations. Notably, COVID-19 has a peculiar prognosis in severe patients with iron dysregulation and hypoxia which is still poorly understood. Studies have shown abnormally low serum iron levels in severe infection but a high iron overload in lung fibrotic tissue. Data from our in-silico structural analysis of the spike protein sequence along with host proteolysis processing suggests that the viral spike protein fragment mimics Hepcidin and is resistant to the major human proteases. This functional spike-derived peptide dubbed "Covidin" thus may be intricately involved with host ferroportin binding and internalization leading to dysregulated host iron metabolism. Here, we propose the possible role of this potentially allogenic mimetic hormone corresponding to severe COVID-19 immunopathology and illustrate that this molecular mimicry is responsible for a major pathway associated with severe disease status. Furthermore, through 3D molecular modeling and docking followed by MD simulation validation, we have unraveled the likely role of Covidin in iron dysregulation in COVID-19 patients. Our meta-analysis suggests the Hepcidin mimetic mechanism is highly conserved among its host range as well as among all new variants to date including Omicron. Extensive analysis of current mutations revealed that new variants are becoming alarmingly more resistant to selective human proteases associated with host defense.

Identifiants

pubmed: 34997606
doi: 10.1002/jcb.30207
pmc: PMC9015563
doi:

Substances chimiques

Iron E1UOL152H7

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

601-619

Subventions

Organisme : Mayo Clinic
ID : STARDOM award (#94551006)

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022 Wiley Periodicals LLC.

Références

World J Emerg Surg. 2021 Mar 8;16(1):9
pubmed: 33685484
Med Hypotheses. 2021 Jan;146:110413
pubmed: 33261916
Medicine (Baltimore). 2021 May 7;100(18):e25832
pubmed: 33950993
J Investig Med. 2021 Jun;69(5):962-969
pubmed: 33849952
Nucleic Acids Res. 2012 Jan;40(Database issue):D370-6
pubmed: 21890895
Nat Commun. 2014 Oct 29;5:4926
pubmed: 25352340
Eur J Epidemiol. 2020 Aug;35(8):763-773
pubmed: 32816244
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Lancet Rheumatol. 2020 Aug;2(8):e458
pubmed: 32835252
Lancet Respir Med. 2020 Jul;8(7):687-695
pubmed: 32386571
J Infect. 2021 Aug;83(2):e15-e17
pubmed: 34146596
Nature. 2021 Apr;592(7852):116-121
pubmed: 33106671
MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1731-1734
pubmed: 34914670
Immunol Res. 2020 Aug;68(4):213-224
pubmed: 32681497
N Engl J Med. 2020 Oct 15;383(16):1522-1534
pubmed: 32558485
Open Forum Infect Dis. 2020 Jun 21;7(7):ofaa250
pubmed: 32661499
Mayo Clin Proc. 2021 Feb;96(2):446-463
pubmed: 33549263
Nucleic Acids Res. 2020 Jan 8;48(D1):D344-D353
pubmed: 31584092
Biotechnol Appl Biochem. 2022 Jun;69(3):1058-1060
pubmed: 33938041
Nat Protoc. 2015 Jun;10(6):845-58
pubmed: 25950237
J Cell Biochem. 2022 Mar;123(3):601-619
pubmed: 34997606
Clin Infect Dis. 2021 Jul 15;73(2):328-331
pubmed: 32750119
Semin Hematol. 2021 Jul;58(3):182-187
pubmed: 34389110
Nutrients. 2021 Jan 23;13(2):
pubmed: 33498631
Sci Rep. 2020 Oct 29;10(1):18689
pubmed: 33122784
Int J Biol Macromol. 2021 Jul 31;183:203-212
pubmed: 33915212
Nature. 2022 Feb;602(7898):664-670
pubmed: 35016195
Biochem Biophys Res Commun. 2007 Apr 27;356(1):312-7
pubmed: 17349976
Sci Rep. 2020 Oct 2;10(1):16384
pubmed: 33009426
Nature. 2021 Jan;589(7843):500-501
pubmed: 33479534
mBio. 2021 Oct 26;12(5):e0198721
pubmed: 34579572
Front Cell Infect Microbiol. 2021 Apr 12;11:644574
pubmed: 33912475
Neurochem Res. 2021 May;46(5):1224-1238
pubmed: 33835366
Int J Mol Sci. 2021 Jun 17;22(12):
pubmed: 34204327
Nat Methods. 2015 Jan;12(1):7-8
pubmed: 25549265
Int J Infect Dis. 2020 Aug;97:303-305
pubmed: 32497811
Cell Res. 2020 Feb;30(2):101-102
pubmed: 31953530
Cell Rep. 2021 Jul 27;36(4):109433
pubmed: 34273271
Methods Mol Biol. 2014;1079:245-62
pubmed: 24170407
Nucleic Acids Res. 2018 Jul 2;46(W1):W438-W442
pubmed: 29846643
Med Sci Monit. 2020 Sep 26;26:e926178
pubmed: 32978363
Sci Rep. 2016 Aug 12;6:28902
pubmed: 27514473
Brief Bioinform. 2019 Mar 25;20(2):638-658
pubmed: 29897410
Stem Cell Reports. 2021 May 11;16(5):1165-1181
pubmed: 33979601
Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W465-9
pubmed: 18424797
Nat Rev Mol Cell Biol. 2014 Dec;15(12):786-801
pubmed: 25415508
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
J Nutr. 2004 Jan;134(1):1-4
pubmed: 14704284
Cell Death Discov. 2020 Nov 25;6:130
pubmed: 33251029
J Clin Med. 2020 Jul 29;9(8):
pubmed: 32751400
Animals (Basel). 2021 Jul 08;11(7):
pubmed: 34359172
Microorganisms. 2021 Jul 20;9(7):
pubmed: 34361977
Science. 2022 May 6;376(6593):eabn4947
pubmed: 35289632
FEBS J. 2019 Oct;286(19):3909-3925
pubmed: 31162791
Gene Rep. 2021 Dec;25:101312
pubmed: 34401607
J Physiol Pharmacol. 2021 Feb;72(1):
pubmed: 34099582
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
J Virol. 2004 Nov;78(22):12672-6
pubmed: 15507655
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
Integr Biol (Camb). 2014 May;6(5):486-510
pubmed: 24714688
Clin Med (Lond). 2021 Jan;21(1):e48-e51
pubmed: 33158957
Pharmaceuticals (Basel). 2019 Nov 25;12(4):
pubmed: 31775259
HGG Adv. 2022 Apr 14;3(2):100095
pubmed: 35224516
Nat Biotechnol. 2021 Sep;39(9):1058-1060
pubmed: 34376850
Cell. 2021 Sep 30;184(20):5189-5200.e7
pubmed: 34537136
Cell Death Dis. 2021 Jan 7;12(1):26
pubmed: 33414455
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Structure. 2011 Dec 7;19(12):1784-95
pubmed: 22153501
J Infect. 2022 Feb;84(2):248-288
pubmed: 34474059
Hum Vaccin Immunother. 2016 Sep;12(9):2351-6
pubmed: 27269431
J Cell Physiol. 2021 Feb;236(2):1131-1147
pubmed: 32643158
Ann Intern Med. 2020 May 05;172(9):577-582
pubmed: 32150748
J Infect. 2021 Nov;83(5):607-635
pubmed: 34384810
Crit Rev Immunol. 2020;40(6):485-496
pubmed: 33900693
Genomics Proteomics Bioinformatics. 2020 Feb;18(1):52-64
pubmed: 32413515
J Biol Chem. 2021 Jan-Jun;296:100536
pubmed: 33716040
J Chem Inf Model. 2011 Oct 24;51(10):2778-86
pubmed: 21919503
Methods. 2021 Nov;195:57-71
pubmed: 33453392
Lancet. 2021 Dec 11;398(10317):2126-2128
pubmed: 34871545
Nat Protoc. 2017 Feb;12(2):255-278
pubmed: 28079879
Protein Cell. 2021 Nov;12(11):832-835
pubmed: 33929695
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Biol Direct. 2020 Oct 16;15(1):19
pubmed: 33066821
J Clin Invest. 2012 Dec;122(12):4635-44
pubmed: 23114598
Nucleic Acids Res. 2016 Jan 4;44(D1):D343-50
pubmed: 26527717
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Nature. 2021 Nov;599(7883):114-119
pubmed: 34488225
ESC Heart Fail. 2020 Dec;7(6):3772-3781
pubmed: 32959998
Int J Infect Dis. 2021 Sep;110:105-110
pubmed: 34242768
Viruses. 2012 Nov 19;4(11):3209-26
pubmed: 23202522
J Cell Physiol. 2012 Feb;227(2):789-800
pubmed: 21503879
Adv Chronic Kidney Dis. 2019 Jul;26(4):298-305
pubmed: 31477260
PLoS One. 2013;8(3):e60077
pubmed: 23555891
Cell Host Microbe. 2021 Apr 14;29(4):508-515
pubmed: 33789086
J Virol. 2020 Feb 14;94(5):
pubmed: 31826992
Lancet Infect Dis. 2022 Jan;22(1):35-42
pubmed: 34461056

Auteurs

Yash Gupta (Y)

Infectious Diseases, Mayo Clinic, Jacksonville, Florida, USA.

Dawid Maciorowski (D)

School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.

Brian Medernach (B)

Department of Medicine, Loyola University Medical Center, Chicago, Illinois, USA.

Daniel P Becker (DP)

Department of Chemistry and Biochemistry, Loyola University Chicago, Chicago, Illinois, USA.

Ravi Durvasula (R)

Infectious Diseases, Mayo Clinic, Jacksonville, Florida, USA.

Claudia R Libertin (CR)

Infectious Diseases, Mayo Clinic, Jacksonville, Florida, USA.

Prakasha Kempaiah (P)

Infectious Diseases, Mayo Clinic, Jacksonville, Florida, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH